Minerva Neurosciences (NASDAQ:NERV) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a strong sell rating in a report issued on Wednesday,Zacks.com reports.

Several other research firms have also recently commented on NERV. Citizens Jmp began coverage on shares of Minerva Neurosciences in a report on Wednesday, April 15th. They set a “market outperform” rating and a $14.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Wednesday, June 24th. Finally, Wall Street Zen raised shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Minerva Neurosciences has a consensus rating of “Reduce” and an average price target of $10.50.

Minerva Neurosciences Price Performance

Shares of NASDAQ NERV opened at $3.92 on Wednesday. The business has a fifty day simple moving average of $4.46 and a 200-day simple moving average of $5.43. The company has a market cap of $187.18 million, a price-to-earnings ratio of -0.14 and a beta of -0.10. Minerva Neurosciences has a 12 month low of $1.79 and a 12 month high of $12.46.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. As a group, sell-side analysts expect that Minerva Neurosciences will post -0.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Minerva Neurosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new position in shares of Minerva Neurosciences during the 2nd quarter worth about $419,000. Seven Fleet Capital Management LP acquired a new stake in Minerva Neurosciences in the 1st quarter valued at approximately $6,855,000. DV Trading LLC acquired a new stake in Minerva Neurosciences in the 1st quarter valued at approximately $5,358,000. Bank of America Corp DE increased its position in Minerva Neurosciences by 78,272.5% in the 1st quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 39,919 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in shares of Minerva Neurosciences by 47,614.0% during the first quarter. Janus Henderson Group PLC now owns 4,294,259 shares of the biopharmaceutical company’s stock worth $25,873,000 after buying an additional 4,285,259 shares during the last quarter. 34.56% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Minerva Neurosciences

Here are the key news stories impacting Minerva Neurosciences this week:

• Positive Sentiment: HC Wainwright’s longer-term projections remain optimistic, calling for positive EPS of $0.64 in fiscal 2029 and $1.67 in fiscal 2030. This indicates the firm still sees potential for meaningful profitability if Minerva’s development programs and commercialization plans succeed.
• Neutral Sentiment: The analyst forecasts EPS of negative $0.15 for fiscal 2028, followed by a return to profitability in 2029. The estimates imply that investors may need to look several years ahead for earnings growth.
• Negative Sentiment: HC Wainwright cut its fiscal 2026 EPS estimate to negative $0.50 from negative $0.20 and reduced its Q3 2026 estimate to negative $0.14 from negative $0.01. The firm also expects Q4 2026 EPS of negative $0.09, compared with its previous estimate of negative $0.01.
• Negative Sentiment: Forecasts for fiscal 2027 were sharply lowered to negative $0.42 per share from positive $4.82. Quarterly 2027 estimates were also reset to approximately negative $0.11 per share, including Q2, Q3 and Q4, signaling substantially weaker near-term earnings expectations.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.